Allergan plans to cut over 1,000 jobs as generic version of eye treatment nears market

Wed, 01/03/2018 - 16:30 EDT - LA Times

Allergan said Wednesday it plans to cut more than 1,000 jobs as it braces for one of its bestselling drugs to face generic competition. Chief Executive Brent Saunders said in November that the company was preparing as though a generic version of Restasis, a dry-eye treatment, would launch in the...

Original article
Login to post comments

Allergan Fires 1,000 In Hopes Of Halting Stock Slide
Not too long ago, Allergan was one of the best performing stocks largely thanks to the rollup nature of its Carl Icahn-sponsored core "roll-up" vehicle of Forrest Labs/Actavis, and led by mercenary activist CEO Brent Saunders, at least until its ill-fated 2015 merger with Pfizer was unceremoniously blocked by the Obama administration in April 2016, when the pharmaceutical company suffered a breach in its upward trajectory and has since suffered a steep decline in the past two ye
Allergan to cut over 1,000 jobs as it works to return to growth
NEW YORK (Reuters) - Allergan Plc on Wednesday said it plans to cut over 1,000 jobs and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.
Allergan is taking an unusual approach to protect the patents on its billion-dollar eye drug — partnering with Native American tribes
AP(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges.
Pfizer-Allergan Merger: The Stakes Just Got Higher
Pfizer Inc. (NYSE:PFE) may have just made it harder for Allergan Plc. (NYSE:AGN) to say no to a merger. Reuters, citing sources, reported on Thursday that Pfizer plans to charge a 2–3% breakup fee if Allergan decides to walk away from the deal.
Here's what the head of Botox-maker Allergan has to say about drug prices, inversions, and why Carl Icahn is not a threat to his long-term plans
MN
REPORT: Pfizer and Allergan are considering making Brent Saunders CEO (PFE, AGN, ACT)
Actavis plc Continues To Hunt Small Deals After Allergan Acquisition
Pharmaceutical giant, Actavis Plc (NYSE: ACT), has announced plans to continue looking for potential acquisition targets after acquiring Allergan, Inc. (NYSE: AGN) in a $66 billion deal. With its completion expected later this year the Actavis-Allergan deal will be 2014’s largest merger in the pharmaceutical industry.
Allergan Submits Prior Approval Supplement For Restasis
In a press release today, Allergan PLC (NYSE:AGN) announced that it has submitted a Prior Approval Supplement (PAS) for Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%. It aims to seek approval of a Multi-Dose Preservative-Free (MDPF) presentation. Restasis are eye drops, used to increase production of tears in patients who suffer from keratoconjuctivitis sicca – a chronic dry eye disease. The lower tear production in the patients is due to ocular inflammation.
Actavis Plc (ACT) To Bring Allergan, Inc. (AGN) CEO On Its Board
Actavis plc (NYSE:ACT) is looking to add Allergan, Inc. (NYSE:AGN) CEO David Pyott to its board of directors, people close to the matter said Thursday.
Brent Saunders Nears $300 Billion Worth of Deals with Allergan PLC Sale; What’s Next on His List?
Allergan PLC (NYSE:AGN) CEO Brent Saunders, who was once referred to as the “Wall Street’s Drug Dealer,” is now nearing $300 billion worth of deals, all put together in less than three years. The latest deal signed by Mr. Saunders is the $155 billion Allergan- Pfizer Inc. (NYSE:PFE) merger, announced on Monday.

Main menu

Secondary menu

Allergan plans to cut over 1,000 jobs as generic version of eye treatment nears market

Related

Latest

Markets Map

Follow Us

Secondary menu